Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Moderna Covid19 Vaccine

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06186856RecruitingPrimary

Epidemiological Data on Mast Cell Pathologies in France

NCT04761822Phase 2Completed

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

Showing all 2 trials

Research Network

Common Treatments

  • Moderna Covid19 Vaccine1
  • Pfizerbiontech Covid19 Vaccine1

Active Sponsors

  • Imagine Institute1
  • Immune Tolerance Network (ITN)1
  • Rho Federal Systems Division, Inc.1
  • National Institute of Allergy and Infectious Diseases (NIAID)1

Top Investigators

  • Rebecca S. Gruchalla, MD, PhD1

    Division of Allergy and Immunology Departments of Internal Medicine and Pediatrics, University of Texas Southwestern

  • N. Franklin Atkinson Jr., MD1

    Graduate Training Program in Clinical Investigation Associate TP Director, Allergy-Immunology Johns Hopkins Asthma & Allergy Center

  • James R. Baker Jr., MD1

    Mary H. Weiser Food Allergy Center and Michigan Nanotechnology Institute for Medicine and the Biological Sciences

Related Conditions

  • Sarscov Infection1
  • Covid191
  • Allergic Reaction1

Activity Timeline